Abstract
Atrial fibrillation (AF) is associated with an elevated risk of cognitive impairment and dementia. The investigation of the cognitive sequelae and alterations of brain structure linked to AF is crucial to help address ensuing health care needs. In this study, we conducted a comprehensive neuropsychological and neuroimaging analysis of 1335 stroke-free individuals with AF (30% women, average age 69.1 years) and compared them with 2683 demographically and cardiovascular risk-matched controls (31% women, average age 69.1 years). Primary study outcomes were neuropsychological test scores and advanced magnetic resonance imaging (MRI) measures of gray matter morphology, gray and white matter microstructure, and white matter hyperintensity (WMH) load. Our analysis identified deficits in attention/executive function, information processing speed and reasoning in individuals with AF. These cognitive impairments were accompanied by a complex imaging profile suggestive of small vessel pathology: (1) reduced cortical thickness and gray matter volume in areas including primary motor, somatosensory and visual cortices as well as the orbitofrontal, lateral prefrontal, posterior insular, and temporal cortices; (2) increased extracellular free-water content in the anterior cingulate, insula, medial prefrontal cortex, medial temporal lobe, and precuneus; (3) widespread microstructural anomalies in the cerebral white matter, marked by lower fractional anisotropy (FA), higher mean diffusivity (MD) and extracellular free-water, and a higher burden of markers of small vessel disease (WMH load and peak width of skeletonized mean diffusivity). Crucially, brain structural differences statistically mediated the link between AF and cognitive performance. By integrating a multimodal analysis approach with extensive clinical and MRI data, our study highlights small vessel pathology as a possible unifying link between AF, cognitive decline and abnormal brain structure. These insights can inform diagnostic approaches and motivate the ongoing implementation of effective therapeutic strategies.
Competing Interest Statement
GT has received fees as consultant or lecturer from Acandis, Alexion, Amarin, Bayer, Boehringer Ingelheim, BristolMyersSquibb/Pfizer, Daichi Sankyo, Portola, and Stryker outside the submitted work. The remaining authors declare no conflicts of interest.
Funding Statement
This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation - Sonderforschungsbereich 936 - 178316478 - C2 (M.P., E.S., B.C., G.T., M.J.) and Schwerpunktprogramm 2041 - 454012190 (S.B.E, G.T.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UKB was ethically approved by the North West Multi-Centre Research Ethics Committee (MREC) and written informed consent was obtained from all participants. Details on the UKB Ethics and Governance framework are provided online (https://www.ukbiobank.ac.uk/media/0xsbmfmw/egf.pdf).15 Data usage is covered by a vote of the ethics committee of the medical faculty of the Heinrich Heine University Duesseldorf.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos